GlaxoSmithKline
GSK
50.33
-0.08
-0.16%
GlaxoSmithKline
US · GSK
#230 by market cap
Listed 1970
50.33
-0.08
-0.16%
Periodic snapshot; not a real-time feed.
· 2026-11-06 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
B-
Momentum strategy signal
Sell
Analyst consensus
Hold
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Jefferies moved from Buy to Hold on 2026-10-28.
Analyst consensus 1 analysts
Hold
Avg price target 55.90 +11.1%
Price target rangecurrent 50.33
Low55.90
Avg55.90
High55.90
Buy 0%
Hold 100%
Sell 0%
Recent ratings (11)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-28 | Jefferies | -- | Hold | 55.90 |
| 2026-08-03 | TD Cowen | -- | Hold | 70.00 |
| 2026-06-11 | TD Cowen | -- | Hold | 70.00 |
| 2026-06-08 | Argus Research | -- | Buy | -- |
| 2026-05-29 | TD Cowen | -- | Hold | 70.00 |
| 2026-05-29 | Jefferies | -- | Buy | 67.10 |
| 2026-02-09 | TD Cowen | -- | Hold | 70.00 |
| 2026-01-07 | Jefferies | -- | Buy | 55.60 |
| 2026-01-06 | Barclays | -- | Sell | -- |
| 2025-12-18 | TD Cowen | -- | Hold | 52.00 |
| 2025-10-29 | BofA Securities | -- | Sell | 23.46 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-28 | Jefferies | Buy → Hold | 55.90 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-28 | -- | ±3.73% | -4.32% (beat) |
| 2026/Q2 | 2026-07-28 | -- | ±3.74% | +3.33% (in line) |
| 2026/Q1 | 2026-04-29 | -- | ±2.98% | -5.64% (beat) |
| 2025/Q4 | 2026-02-04 | -- | ±6.00% | +7.29% (beat) |
| 2025/Q3 | 2025-10-29 | -- | ±3.87% | +5.10% (beat) |
| 2025/Q2 | 2025-07-30 | -- | ±4.40% | +3.45% (in line) |
| 2025/Q1 | 2025-04-30 | -- | ±4.00% | +2.26% (in line) |
| 2024/Q4 | 2025-02-05 | -- | ±4.68% | +8.21% (beat) |
| 2024/Q3 | 2024-10-30 | -- | ±5.81% | -3.04% (in line) |
| 2024/Q2 | 2024-07-31 | -- | ±5.56% | -2.51% (in line) |
| 2024/Q1 | 2024-05-01 | -- | ±4.91% | +2.73% (in line) |
| 2023/Q3 | 2023-11-01 | -- | ±3.94% | -3.14% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-06 19:30:03 · For reference only, not investment advice and not tailored to your situation.
GlaxoSmithKline discussion 0 comments